Bridgebio and Affiliate Phoenix Tissue Repair Presents Results of PTR-01 in P-II Trial for Recessive Dystrophic Epidermolysis Bullosa at SID 2022
Shots:
- The P-II trial evaluates the safety, tolerability & effect of PTR-01 on wound healing along with other EPs in patients with RDEB
- The results showed ≥50% reduction in wound surface area @120 Days over 80% of target wounds while clinician assessment of the same target lesions showed a similar level of efficacy & wound improvement, 15 out of 26 wounds (58%) met the response criteria of ≥2-point increase on the wound-specific scale at 15 days after initiating treatment, 69% met the response criteria, 67% were responders @120 Day, was well-tolerated over 4mos. treatment period
- Improvement in PROs, all patients who completed the study reported a pain reduction, 36% mean reduction in total pain from the end of the study
Ref: Bridgebio | Image: Bridgebio
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
